The emerging role of immunotherapy in gastric and esophageal adenocarcinoma

Future Oncology

Volumn 12, Issue 15, 2016, Pages 1833-1846

  Bockorny, Bruno ^a,b   Pectasides, Eirini ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

esophageal adenocarcinoma; gastric adenocarcinoma; immune checkpoint inhibitors; immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; AVELUMAB; BIOLOGICAL MARKER; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DOCETAXEL; DURVALUMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IMMUNE CHECKPOINT INHIBITOR; IPILIMUMAB; IRINOTECAN; NIVOLUMAB; OXALIPLATIN; PACLITAXEL; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; RAMUCIRUMAB; TICILIMUMAB; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER IMMUNOTHERAPY; CHROMOSOMAL INSTABILITY; DISEASE MARKER; DRUG RESPONSE; EPSTEIN BARR VIRUS; ESOPHAGEAL ADENOCARCINOMA; HUMAN; MICROSATELLITE INSTABILITY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH ADENOCARCINOMA; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; IMMUNOTHERAPY; PROCEDURES; STOMACH NEOPLASMS;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; STOMACH NEOPLASMS;

EID: 84979787929     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon-2016-0103     Document Type: Review

References (103)

1. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359-E386 (2015)
2. Wagner AD. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. 24(18), 2903-2909 (2006)
3. Bang Y-J, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet 376(9742), 687-697 (2010)
4. Fuchs CS, Tomasek J, Yong CJ et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, Phase 3 trial. Lancet 383(9911), 31-39 (2014)
5. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517), 202-209 (2014)
6. Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 137(3), 824-833 (2009)
7. Liu Y, Yang W, Pan Y, Ji J, Lu Z, Ke Y. Genome-wide analysis of Epstein-Barr virus (EBV) isolated from EBV-associated gastric carcinoma (EBVaGC). Oncotarget 7(4), 4903-4914 (2015)
8. Akiba S, Koriyama C, Herrera-Goepfert R, Eizuru Y. Epstein-Barr virus associated gastric carcinoma: epidemiological and clinicopathological features. Cancer Sci. 99(2), 195-201 (2008)
9. Kim J, Lee HS, Bae SI, Lee YM, Kim W-H. Silencing and CpG island methylation of GSTP1 is rare in ordinary gastric carcinomas but common in Epstein-Barr virus-associated gastric carcinomas. Anticancer Res. 25(6B), 4013-4019 (2005)
10. Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin. Chim. Acta 424, 53-65 (2013)
11. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192(7), 1027-1034 (2000)
12. Oda K, Tamaru J, Takenouchi T et al. Association of Epstein-Barr virus with gastric carcinoma with lymphoid stroma. Am. J. Pathol. 143(4), 1063-1071 (1993)
13. Saiki Y, Ohtani H, Naito Y, Miyazawa M, Nagura H. Immunophenotypic characterization of Epstein-Barr virus-associated gastric carcinoma: massive infiltration by proliferating CD8+ T-lymphocytes. Lab. Invest. 75(1), 67-76 (1996)
14. Kuzushima K, Nakamura S, Nakamura T et al. Increased frequency of antigen-specific CD8+ cytotoxic T lymphocytes infiltrating an Epstein-Barr virus-associated gastric carcinoma. J. Clin. Invest. 104(2), 163-171 (1999)
15. Kim SY, Park C, Kim H-J et al. Deregulation of immune response genes in patients with Epstein-Barr virus-associated gastric cancer and outcomes. Gastroenterology 148(1), 137-147.e9 (2015)
16. Camargo MC, Kim W-H, Chiaravalli AM et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut 63(2), 236-243 (2014)
17. Song H-J, Srivastava A, Lee J et al. Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology 139(1), 84-92.e2 (2010)
18. Strong MJ, Xu G, Coco J et al. Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. PLoS Pathog. 9(5), e1003341 (2013)
19. Chen BJ, Chapuy B, Ouyang J et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin. Cancer Res. 19(13), 3462-3473 (2013)
20. Twa DDW, Chan FC, Ben-Neriah S et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 123(13), 2062-2065 (2014)
21. Paydas S, BaǦir E, Seydaoglu G, Ercolak V, Ergin M. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. Ann. Hematol. 94(9), 1545-1552 (2015)
22. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372(4), 311-319 (2015)
23. Falchetti M, Saieva C, Lupi R et al. Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival. Hum. Pathol. 39(6), 925-932 (2008)
24. Kim J-Y, Shin NR, Kim A et al. Microsatellite instability status in gastric cancer: a reappraisal of its clinical significance and relationship with mucin phenotypes. Korean J. Pathol. 47(1), 28-35 (2013)
25. Choi YY, Bae JM, An JY et al. Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis. J. Surg. Oncol. 110(2), 129-135 (2014)
26. Shigeyasu K, Nagasaka T, Mori Y et al. Clinical significance of MLH1 methylation and CpG island methylator phenotype as prognostic markers in patients with gastric cancer. PLoS ONE 10(6), e0130409 (2015)
27. Grogg KL, Lohse CM, Pankratz VS, Halling KC, Smyrk TC. Lymphocyte-rich gastric cancer: associations with Epstein-Barr virus, microsatellite instability, histology, and survival. Mod. Pathol. 16(7), 641-651 (2003)
28. Kim K-J, Lee KS, Cho HJ et al. Prognostic implications of tumor-infiltrating FoxP3+ regulatory T cells and CD8+ cytotoxic T cells in microsatellite-unstable gastric cancers. Hum. Pathol. 45(2), 285-293 (2014)
29. Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am. J. Pathol. 158(2), 527-535 (2001)
30. Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 91(12), 2417-2422 (2001)
31. Young J, Simms LA, Biden KG et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am. J. Pathol. 159(6), 2107-2116 (2001)
32. Snyder A, Makarov V, Merghoub T et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371(23), 2189-2199 (2014)
33. Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230), 124-128 (2015)
34. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372(26), 2509-2520 (2015)
35. Geigl JB, Obenauf AC, Schwarzbraun T, Speicher MR. Defining 'chromosomal instability'. Trends Genet. 24(2), 64-69 (2008)
36. Gordon DJ, Resio B, Pellman D. Causes and consequences of aneuploidy in cancer. Nat. Rev. Genet. 13(3), 189-203 (2012)
37. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45(10), 1127-1133 (2013)
38. Das K, Gunasegaran B, Tan IB, Deng N, Lim KH, Tan P. Mutually exclusive FGFR2, HER2 and KRAS gene amplifications in gastric cancer revealed by multicolour FISH. Cancer Lett. 353(2), 167-175 (2014)
39. Janbabai G, Oladi Z, Farazmandfar T, Taghvaei T, Naghshvar F. The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR. J. Cancer Res. Clin. Oncol. 141(11), 1945-1952 (2015)
40. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 500(7463), 415-421 (2013)
41. Koeppel M, Garcia-Alcalde F, Glowinski F, Schlaermann P, Meyer TF. Helicobacter pylori infection causes characteristic DNA damage patterns in human cells. Cell Rep. 11(11), 1703-1713 (2015)
42. Kao JY, Zhang M, Miller MJ et al. Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology 138(3), 1046-1054 (2010)
43. Das S, Suarez G, Beswick EJ, Sierra JC, Graham DY, Reyes VE. Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J. Immunol. 176(5), 3000-3009 (2006)
44. Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol. Biomarkers Prev. 19(6), 1468-1470 (2010)
45. Hur C, Miller M, Kong CY et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 119(6), 1149-1158 (2013)
46. Dulak AM, Stojanov P, Peng S et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 45(5), 478-486 (2013)
47. Stachler MD, Taylor-Weiner A, Peng S et al. Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet. 47(9), 1047-1055 (2015)
48. Ross-Innes CS, Becq J, Warren A et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nat. Genet. 47(9), 1038-1046 (2015)
49. Thompson RH, Gillett MD, Cheville JC et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl Acad. Sci. USA 101(49), 17174-17179 (2004)
50. Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66(7), 3381-3385 (2006)
51. Hino R, Kabashima K, Kato Y et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116(7), 1757-1766 (2010)
52. Gadiot J, Hooijkaas AI, Kaiser ADM, van Tinteren H, van Boven H, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 117(10), 2192-2201 (2011)
53. Taube JM, Anders RA, Young GD et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4(127), 127ra37 (2012)
54. Ohigashi Y. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 11(8), 2947-2953 (2005)
55. Chen L-J, Sun J, Wu H-Y et al. B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol. Immunother. 60(7), 1047-1055 (2011)
56. Derks S, Nason KS, Liao X et al. Epithelial PD-L2 expression marks Barrett's esophagus and esophageal adenocarcinoma. Cancer Immunol. Res. 3(10), 1123-1129 (2015)
57. Wu C, Zhu Y, Jiang J, Zhao J, Zhang X-G, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 108(1), 19-24 (2006)
58. Hou J, Yu Z, Xiang R et al. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Exp. Mol. Pathol. 96(3), 284-291 (2014)
59. Zhang L, Qiu M, Jin Y et al. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. Int. J. Clin. Exp. Pathol. 8(9), 11084-11091 (2015)
60. Jiang J, Zhu Y, Wu C et al. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol. Immunother. 59(11), 1707-1714 (2010)
61. Saito H, Kuroda H, Matsunaga T, Osaki T, Ikeguchi M. Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. J. Surg. Oncol. 107(5), 517-522 (2013)
62. Zhang R, Liu H, Li F, Li H, Yu J, Ren X. The correlation between the subsets of tumor infiltrating memory T cells and the expression of indoleamine 2,3-dioxygenase in gastric cancer. Dig. Dis. Sci. 58(12), 3494-3502 (2013)
63. Jiang J, Jin M-S, Kong F et al. Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. PLoS One 8(12), e81799 (2013)
64. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252-264 (2012)
65. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat. Rev. Immunol. 2(2), 116-126 (2002)
66. Krummel MF. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182(2), 459-465 (1995)
67. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256), 1734-1736 (1996)
68. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175(11), 7746-7754 (2005)
69. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15(8), 486-499 (2015)
70. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin. Cancer Res. 19(19), 5300-5309 (2013)
71. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012)
72. Brahmer JR, Tykodi SS, Chow LQM et al. Safety and activity of anti-PD-L1 antibody in Patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012)
73. Powles T, Eder JP, Fine GD et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528), 558-562 (2014)
74. McDermott DF, Drake CG, Sznol M et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J. Clin. Oncol. 33(18), 2013-2020 (2015)
75. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010)
76. Eggermont AMM, Chiarion-Sileni V, Grob J-J et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, Phase 3 trial. Lancet Oncol. 16(5), 522-530 (2015)
77. Ralph C, Elkord E, Burt DJ et al. Modulation of lymphocyte regulation for cancer therapy: a Phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin. Cancer Res. 16(5), 1662-1672 (2010)
78. Wilke H, Muro K, Van Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised Phase 3 trial. Lancet Oncol. 15(11), 1224-1235 (2014)
79. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15(23), 7412-7420 (2009)
80. Herbst RS, Soria J-C, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528), 563-567 (2014)
81. Segal NH, Antonia SA, Brahmer JR et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. ASCO Meeting Abstracts 32(15 Suppl.), Abstract 3002 (2014)
82. Bang Y-J, Chung H-C, Shankaran V et al. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. ASCO Meeting Abstracts 33(15 Suppl.), Abstract 4001 (2015)
83. Le DT, Bendell JC, Calvo E et al. Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): results from the CheckMate-032 study. ASCO Gastrointestinal Cancer Symposium Meeting Abstracts 34(4 Suppl.), 6 (2016)
84. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol. Res. 23(2), 263-272 (2001)
85. Oyama T, Ran S, Ishida T et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J. Immunol. 160(3), 1224-1232 (1998)
86. Osada T, Chong G, Tansik R et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 57(8), 1115-1124 (2008)
87. Kandalaft LE, Motz GT, Busch J, Coukos G. Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin. Curr. Top. Microbiol. Immunol. 344, 129-148 (2011)
88. Voron T, Colussi O, Marcheteau E et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J. Exp. Med. 212(2), 139-148 (2015)
89. Hodi FS, Lawrence D, Lezcano C et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol. Res. 2(7), 632-642 (2014)
90. Arnould L, Gelly M, Penault-Llorca F et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer 94(2), 259-267 (2006)
91. Stagg J, Loi S, Divisekera U et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl Acad. Sci. USA 108(17), 7142-7147 (2011)
92. Böger C, Behrens H-M, Mathiak M, Krüger S, Kalthoff H, Röcken C. PD-L1 is an independent prognostic predictor in gastric cancer of western patients. Oncotarget doi:10.18632/oncotarget.8169 (2016) (Epub ahead of print)
93. Jiang J, Xu N, Wu C et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res. 26(3B), 2237-2242 (2006)
94. Zhao H, Fan Y, Li H et al. Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: a retrospective study of 165 patients. Cancer Biother. Radiopharm. 28(4), 303-309 (2013)
95. Shi L, Zhou Q, Wu J et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol. Immunother. 61(12), 2251-2259 (2012)
96. Jiang J-T, Shen Y-P, Wu C-P et al. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J. Gastroenterol. 16(48), 6155-6162 (2010)
97. Chang AE, Redman BG, Whitfield JR et al. A Phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 8(4), 1021-1032 (2002)
98. Figdor CG, de Vries IJM, Lesterhuis WJ, Melief CJM. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10(5), 475-480 (2004)
99. Sadanaga N, Nagashima H, Mashino K et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin. Cancer Res. 7(8), 2277-2284 (2001)
100. Tanaka F, Haraguchi N, Isikawa K, Inoue H, Mori M. Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas. Oncol Rep. 20(5), 1111-1116 (2008)
101. Kono K, Takahashi A, Sugai H et al. Dendritic cells pulsed with HER-2/ neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin. Cancer Res. 8(11), 3394-3400 (2002)
102. Melero I, Gaudernack G, Gerritsen W et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 11(9), 509-524 (2014)
103. Shankaran V, Muro K, Bang Y-J et al. Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475). ASCO Meeting Abstracts 33(15 Suppl.), Abstract 3026 (2015)